Pfizer and BioNTech Submit Data to EMA for Omicron BA.1 Adapted Bivalent Vaccine Candidate
Potential COVID-19 jab would apply to individuals age 12 and older
Pfizer and BioNTech have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted bivalent COVID-19 vaccine candidate, based on the BA.1 sub-lineage, for individuals 12 years of age and older.
The companies previously announced safety, tolerability, and immunogenicity data from a Phase 2/3 trial that found a 30 µg booster dose of the Omicron-adapted bivalent vaccine candidate produced a superior immune response against Omicron BA.1, as compared to the companies’ current COVID shot. The bivalent vaccine candidate was well-tolerated with a favorable safety profile.
The involved parties previously shared these data with FDA to support a potential variant-adapted vaccine, and they continue to submit additional data as advised by the agency.
Elevate Your Commercial Operations with Close-up CRM
September 6th 2024Discover a powerful, cost-effective, and robust CRM platform that maximizes your budget. Seamlessly integrate data from any source, streamline marketing efforts, and optimize HCP promotion, key account management, and digital marketing campaigns. Reduce CRM costs and reallocate funds to enhance data analytics, market research, and human capital, boosting overall commercial operations impact.
AI-Enabled Pharma CRM Driving Intelligent Customer Engagement
September 6th 2024Discover our unparalleled CRM solution that integrates AI/ML for enhanced stability, security, and performance. Leverage our team of 1000+ experts and 25K+ data provider partners. Our cloud-based SaaS model allows rapid global deployment and scalability, while our clean UX focuses on intuitive AI experience and rapid user adoption. Ensure swift 80% physician onboarding with our intuitive AI platform, speeding strategic integration.
